华昊中天医药-B(02563.HK) 公布,集团的重要海外管线之一,优替德隆胶囊“UTD2”联合卡培他滨和奥沙利铂一线治疗PD -L1阴性的局部晚期或转移性胃或胃食管交界处腺癌的国际多中心II/ III期注册临床研究“BG 02 -2404”已获美国食品药品管理局“FDA”批准。(de/d)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.